3.51

1.74% 0.06

Pre-market: 3.50 -0.010 -0.28%

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.51, with a volume of 3.33M. It is up +1.74% in the last 24 hours and down -47.53% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Previous Close:

$3.45

Open:

$3.52

24h Volume:

3.33M

Relative Volume:

1.95

Market Cap:

$233.88M

Revenue:

$80.00M

Net Income/Loss:

$-76.12M

P/E Ratio:

-3.0615

EPS:

-1.1465

Net Cash Flow:

$-63.88M

1W Performance:

+2.03%

1M Performance:

-47.53%

6M Performance:

-72.83%

1Y Performance:

-48.76%

1-Day Range:

$3.47

$3.62

1-Week Range:

$3.34

$3.64

52-Week Range:

$2.83

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2026-08-04

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	3.51	233.88M	80.00M	-76.12M	-63.88M	-1.1465
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Initiated	JP Morgan	Overweight
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

Jun 14, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire

Jun 14, 2026

Fulcrum plunges after discontinuing lead program - MSN

Jun 14, 2026

Jun 12, 2026

What's going on with Fulcrum Therapeutics stock on Thursday? - MSN

Jun 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 12, 2026

Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart

Jun 12, 2026

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits

Jun 12, 2026

Jun 11, 2026

Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks

Jun 11, 2026

Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan

Jun 11, 2026

Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com

Jun 11, 2026

A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance

Jun 11, 2026

Jun 10, 2026

Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan

Jun 10, 2026

FULC stock crashes as cancer risk forces its only drug program's end - MSN

Jun 10, 2026

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - NewMediaWire

Jun 10, 2026

Jun 09, 2026